KR960704555A - 5-알파 환원효소 억제제를 사용한 안드로겐성 탄모증의 치료 방법(Method of treating androgenic alopecia with 5-alpha reductase inhibitors) - Google Patents

5-알파 환원효소 억제제를 사용한 안드로겐성 탄모증의 치료 방법(Method of treating androgenic alopecia with 5-alpha reductase inhibitors) Download PDF

Info

Publication number
KR960704555A
KR960704555A KR1019960701921A KR19960701921A KR960704555A KR 960704555 A KR960704555 A KR 960704555A KR 1019960701921 A KR1019960701921 A KR 1019960701921A KR 19960701921 A KR19960701921 A KR 19960701921A KR 960704555 A KR960704555 A KR 960704555A
Authority
KR
South Korea
Prior art keywords
dose
day
reductase
inhibitor
androgenetic alopecia
Prior art date
Application number
KR1019960701921A
Other languages
English (en)
Other versions
KR100375083B1 (ko
Inventor
제이. 검리 글렌
디. 커프맨 케이쓰
스토너 엘리자베쓰
왈드스트레이처 죠안
Original Assignee
도나 엘. 폴록
머크 앤드 캄파니, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22482390&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR960704555(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 도나 엘. 폴록, 머크 앤드 캄파니, 인코포레이티드 filed Critical 도나 엘. 폴록
Publication of KR960704555A publication Critical patent/KR960704555A/ko
Application granted granted Critical
Publication of KR100375083B1 publication Critical patent/KR100375083B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A61Q7/02—Preparations for inhibiting or slowing hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

본 발명은 안드로겐성 탈모증의 치료를 필요로 하는 환자에게 피나스테라이드와 같은 5α-환원효소 2억제제를 5㎎/일 이하의 용량으로 투여하여 안드로겐성 탈모증을 치료 및/또는 전환시키고 모발 성장을 촉진시키는 방법 및 심상성 좌창, 지루 및 여성 조모증을 치료하는 방법에 관한 것이다.

Description

5-알파 환원효소 억제제를 사용한 안드로겐성 탄모증의 치료 방법(Method of treating androgenic alopecia with 5-alpha reductase inhibitors)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (27)

  1. 안드로겐성 탈모증 치료를 필요로 하는 환자에게 5α-환원효소 2 억제제를 5.0㎎/일 이하의 용량으로 투여함을 포함하는 안드로겐성 탈모증의 치료 방법.
  2. 제1항에 있어서, 용량이 약 0.01 내지 3.0㎎/일인 방법.
  3. 제1항에 있어서, 용량이 약 0.05 내지 1.0㎎/일인 방법.
  4. 제1항에 있어서, 용량이 약 0.05㎎/일인 방법.
  5. 제1항에 있어서, 용량이 약 0.2㎎/일인 방법.
  6. 제1항에 있어서, 안드로겐성 탈모증이 남성형 대머리증인 방법.
  7. 제1항에 있어서, 5α-환원효소 2 억제제가 경구 투여되는 방법.
  8. 제1항에 있어서, 5α-환원효소 2 억제제가 국소 투여되는 방법.
  9. 제1항에 있어서, 5α-환원효소 2 억제제가 일반식(Ⅰ)의, 화합물 또는 이의 약제학적으로 허용되는 염인 방법.
    상기 식에서, R1은 수소, 메틸 또는 에틸이고, R2는 탄소수 1 내지 2의 이상의 저급 알킬 치환체 및/또는 하나 이상의 할로겐(Cl, F 또는 Br) 치환체를 함유하거나 함유하지 않는 탄소수 1 내지 12의 직쇄 및 측쇄 알킬 또는 모노 사이클릭 아릴중에서 선택된 탄화수소 라디칼이며, R′는 수소 또는 메틸이고, R″는 수소 또는 β-메틸이며, R″′는 수소, α-메틸 또는 β-메틸이다.
  10. 제1항에 있어서, 5α-환원효소 2 억제제가 일반식(Ⅱ)의 화합물 또는 이의 약제학적으로 허용되는 염인 방법.
    상기 식에서, R1은 수소 또는 메틸이고, R3는 탄소수 4 내지 8의 측쇄 알킬이다.
  11. 안드로겐성 탈모증 치료를 필요로 하는 환자에게 17β-(N-t-부틸카바모일)-4-아자-5α-안드로스트-1-엔-3-온을 5.0㎎/일 이하의 용량으로 투여함을 포함하는 안드로겐성 탈모증의 치료 방법.
  12. 제11항에 있어서, 안드로겐성 탈모증이 남성형 대머리증인 방법.
  13. 제11항에 있어서, 용량이 약 0.01 내지 3.0㎎/일인 방법.
  14. 제11항에 있어서, 용량이 약 0.05 내지 1.0㎎/일인 방법.
  15. 제11항에 있어서, 용량이 약 0.05㎎/일인 방법.
  16. 제11항에 있어서, 용량이 약 0.02㎎/일인 방법.
  17. 제11항에 있어서, 17β-(N-t-부틸카바모일)-4-이자-5α-안드로스트-1-엔-3-온이 국소 투여되는 방법.
  18. 제11항에 있어서, 17β-(N-t-부틸카바모일)-4-이자-5α-안드로스트-1-엔-3-온이 경구 투여되는 방법.
  19. 제18항에 있어서, 용량이 약 0.2㎎/일인 방법.
  20. 제18항에 있어서, 용량이 약 0.05㎎/일인 방법.
  21. 안드로겐성 탈모증 치료를 필요로 하는 환자에게 5α-환원효소 2 억제제를 5.0㎎/일 이하의 용량으로 투여함을 포함하는 안드로겐성 탈모증의 억제 및 전환 방법.
  22. 치료를 필요로 하는 환자에게 5α-환원효소 2 억제제를 5.0㎎/일 이하의 용량으로 투여함을 포함하여 사람 두피에서 5α-디하이드로-테스토스테론의 수준을 저하시키는 방법.
  23. 제22항에 있어서, 용량이 약 0.01 내지 3.0㎎/일인 방법.
  24. 제22항에 있어서, 용량이 약 0.05 내지 1.0㎎/일인 방법.
  25. 제22항에 있어서, 용량이 약 0.05㎎/일인 방법.
  26. 제22항에 있어서, 용량이 약 0.2㎎/일인 방법.
  27. 제22항에 있어서, 용량이 약 1.0㎎/일인 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960701921A 1993-10-15 1994-10-11 5-알파환원효소억제제를함유하는안드로겐성탈모증치료용약제학적조성물 KR100375083B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US13852093A 1993-10-15 1993-10-15
US08/138520 1993-10-15
US08/138,520 1993-10-15
US08/214,905 1994-03-17
US08/214905 1994-03-17
US08/214,905 US5547957A (en) 1993-10-15 1994-03-17 Method of treating androgenic alopecia with 5-α reductase inhibitors

Publications (2)

Publication Number Publication Date
KR960704555A true KR960704555A (ko) 1996-10-09
KR100375083B1 KR100375083B1 (ko) 2003-06-09

Family

ID=22482390

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960701921A KR100375083B1 (ko) 1993-10-15 1994-10-11 5-알파환원효소억제제를함유하는안드로겐성탈모증치료용약제학적조성물

Country Status (8)

Country Link
US (4) US5547957A (ko)
EP (1) EP0776664A2 (ko)
KR (1) KR100375083B1 (ko)
CO (1) CO4290359A1 (ko)
HK (1) HK1000933A1 (ko)
MY (2) MY123960A (ko)
YU (1) YU49026B (ko)
ZA (1) ZA948064B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200128919A (ko) 2019-05-07 2020-11-17 (주)케어젠 트롤록스-펩타이드 결합체 및 그의 용도

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547957A (en) * 1993-10-15 1996-08-20 Merck & Co., Inc. Method of treating androgenic alopecia with 5-α reductase inhibitors
TW382595B (en) * 1993-10-15 2000-02-21 Merck & Co Inc Pharmaceutical composition for use in arresting and reversing androgenic alopecia
CA2173863C (en) * 1993-10-21 2003-05-13 Philippe L. Durette 16-substituted-4-aza-androstane 5-alpha-reductase isozyme 1 inhibitors
USRE39056E1 (en) 1995-09-15 2006-04-04 Merck & Co, Inc. 4-Azasteroids for treatment of hyperandrogenic conditions
AU704933B2 (en) * 1995-10-19 1999-05-06 Merck & Co., Inc. 16-substituted-6-aza-steroid 5-alpha-reductase inhibitors
US5679378A (en) * 1995-12-18 1997-10-21 Olim Industries Of Israel, North America, Ltd. Method and material for hair therapy
US5935968A (en) * 1997-03-17 1999-08-10 Merck & Co., Inc. Methods for treating polycystic ovary syndrome
US6348348B1 (en) * 1998-04-07 2002-02-19 The Carnegie Institution Of Washington Human hairless gene and protein
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
JP4106454B2 (ja) 2001-10-31 2008-06-25 コリアナ・コズメティック・カンパニー・リミテッド フィタンジオールアミンを含むニキビ治療用組成物（Ｃｏｍｐｏｓｉｔｉｏｎｓｆｏｒｔｒｅａｔｉｎｇａｃｎｅｃｏｍｐｒｉｓｉｎｇｐｈｙｔａｎｄｉｏｌａｍｉｎｅ）
US7790706B2 (en) * 2002-06-14 2010-09-07 The University Of Edinburgh Treatment of inflammation with 5α reduced metabolites
GB0213745D0 (en) * 2002-06-14 2002-07-24 Univ Edinburgh Enzyme
IL156670A0 (en) * 2003-06-26 2004-01-04 Zvi Zolotariov Aloe suppositories
US7550593B2 (en) * 2003-07-03 2009-06-23 Cipla Limited Process for the preparation of finasteride Form I
US20050136015A1 (en) * 2003-12-17 2005-06-23 McKie Derrick B. Topical use of halosalicylic acid derivatives
JP2007522201A (ja) * 2004-02-12 2007-08-09 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 毛成長の刺激方法
GB0407329D0 (en) * 2004-03-31 2004-05-05 Danisco Process
US7979110B1 (en) * 2004-09-23 2011-07-12 Orbital Research Inc. Method for accurate placement of electrodes
EP1824495A2 (en) 2004-12-03 2007-08-29 ProteoSys AG Finasteride, dutasteride and related compounds for preventing/treating neurologically-associated disorders
US20060263452A1 (en) * 2005-05-17 2006-11-23 Alwyn Dowell Topical composition containing essential oils
US20070167899A1 (en) * 2006-01-19 2007-07-19 Strom Randy A Compression apparatus and method for stimulating hair growth
US20090076058A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched finasteride
US20090203628A1 (en) * 2008-02-12 2009-08-13 Jan Marini Composition, Method And Kit For Treating Skin Disorders And Improving Skin Condition
US20090233954A1 (en) * 2008-03-12 2009-09-17 Goren Andy Ofer Methods and systems for prognosis of a patient's response to treatment of androgenetic skin disorders
EP2378872A4 (en) 2008-12-18 2012-05-16 B Eugene Guthery TREATMENT PLAN FOR ACNE VULGARIS
FR2954124B1 (fr) * 2009-12-18 2012-04-06 Fabre Pierre Dermo Cosmetique Utilisation du 2,3-dihydroxypropyl dodecanoate pour le traitement de la seborrhee
CN103313693A (zh) * 2010-08-05 2013-09-18 传世健康护理控股有限公司 用于刺激毛发生长的方法
US8604047B2 (en) * 2010-08-10 2013-12-10 Elorac, Inc. Method and composition for treating nodulocystic and conglobate acne vulgaris
US20140322148A1 (en) * 2011-11-25 2014-10-30 Adrianna Janell Jackson Oil Compositions and Methods for Increasing Hair Growth and/or Preventing Hair Loss
KR102064488B1 (ko) * 2019-04-18 2020-01-13 주식회사 엠진 홍삼 추출물 등을 이용한 발모 촉진 또는 탈모 억제용 조성물

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377584A (en) * 1978-04-13 1983-03-22 Merck & Co., Inc. 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
AU527030B2 (en) * 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
US4220775A (en) * 1979-03-15 1980-09-02 Merck & Co., Inc. Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors
US4396615A (en) * 1981-06-24 1983-08-02 Duke University Method of treating androgen-related disorders
US4885289A (en) * 1983-12-12 1989-12-05 Breuer Miklos M Alteration of character of male beard growth
US5571817A (en) * 1984-02-27 1996-11-05 Merck & Co., Inc. Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones]
NZ211145A (en) * 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
US4859681A (en) * 1984-02-27 1989-08-22 Merck & Co., Inc. 17 α-Acyl-4-aza-5a-androst-1-en-3-ones as 5 alpha-reductase inhibitors
US5120742A (en) * 1984-02-27 1992-06-09 Merck & Co., Inc. 17 β-acyl-4-aza-5 α-androst-1-ene-3-ones as 5 α-reductase inhibitors
US4760071A (en) * 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
US5151429A (en) * 1984-02-27 1992-09-29 Merck & Co., Inc. 17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α reductase inhibitors
US5049562A (en) * 1984-02-27 1991-09-17 Merck & Co., Inc. 17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α-reductase inhibitors
US4684635A (en) * 1984-05-11 1987-08-04 Norman Orentreich Compositions and methods for inhibiting the action of androgens
US5053403A (en) * 1984-05-11 1991-10-01 Norman Orentreich Methods for treatment of male-pattern baldness
DE3888994T2 (de) * 1987-04-03 1994-11-03 Merck & Co Inc Behandlung von androgener Alopecia mit 17-beta-n-mono-substituierten-carbamoyl-4-aza-5-alpha-androst-1-en-3-onen.
EP0285383B1 (en) 1987-04-03 1994-03-16 Merck & Co. Inc. Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones
US5228431A (en) * 1990-04-26 1993-07-20 Giarretto Ralph R Drug-free method for treatment of the scalp for therapeutic purposes
US5162332A (en) * 1990-06-20 1992-11-10 Merck & Co., Inc. Selected 17 β-polyaroyl-4-aza-5 α-androst-1-en-3-ones as steroidal reductase inhibitors
US5098908A (en) * 1990-06-20 1992-03-24 Merck & Co., Inc. 17β-hydroxybenzoyl-4-aza-5α-androst-1-en-3-ones as testosterone reductase inhibitors
CA2085605C (en) * 1990-08-10 2003-03-11 Arthur Robert Diani Stimulation of hair growth with potassium channel openers and 5alpha-reductase inhibitors
US5175155A (en) * 1991-10-07 1992-12-29 Sterling Winthrop Inc. Win 49596-finasteride method of use and compositions
JPH07508039A (ja) 1992-05-20 1995-09-07 メルク　エンド　カンパニー　インコーポレーテッド ４−アザステロイドのエステル誘導体
UA35589C2 (uk) * 1992-05-21 2001-04-16 Андорешерш Інк. ІНГІБІТОРИ ТЕСТОСТЕРОН 5-<font face="Symbol">a</font>-РЕДУКТАЗИ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ІНГІБУВАННЯ АКТИВНОСТІ ТЕСТОСТЕРОН 5-<font face="Symbol">a</font>-РЕДУКТАЗИ
US5795882A (en) * 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
US5407944A (en) 1993-02-19 1995-04-18 Goldman; Boris E. Compositions and methods for promoting hair growth
EP0711164B1 (en) * 1993-06-28 1997-09-17 Merck & Co. Inc. 4-aza-pregnane 5-alpha-reductase isozyme 1 inhibitors
US5438061A (en) 1993-07-16 1995-08-01 Merck & Co., Inc. 7-substituted-δ4-6-azasteroid derivatives as 5α-reductase inhibitors
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
TW382595B (en) * 1993-10-15 2000-02-21 Merck & Co Inc Pharmaceutical composition for use in arresting and reversing androgenic alopecia
US5547957A (en) * 1993-10-15 1996-08-20 Merck & Co., Inc. Method of treating androgenic alopecia with 5-α reductase inhibitors
CA2173863C (en) * 1993-10-21 2003-05-13 Philippe L. Durette 16-substituted-4-aza-androstane 5-alpha-reductase isozyme 1 inhibitors
US5708001A (en) * 1993-12-17 1998-01-13 Glaxo Wellcome Inc. Substituted 6-azaandrostenones
US5525608A (en) * 1994-04-20 1996-06-11 Merck & Co., Inc. 17b-aryl-4-aza-steroid derivatives useful as 5-alpha-reductase inhibitors
US5512555A (en) * 1994-07-21 1996-04-30 Merck & Co., Inc. Method of treating sweat-related conditions using finasteride, epristeride and a cholestan-3-one
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
US5595996A (en) * 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
AU704933B2 (en) * 1995-10-19 1999-05-06 Merck & Co., Inc. 16-substituted-6-aza-steroid 5-alpha-reductase inhibitors
US5763361A (en) * 1995-10-23 1998-06-09 Merck & Co., Inc. 17-alkyl-7-substituted-4-aza steroid derivatives as 5-α-reductase inhibitors
US5777134A (en) * 1995-10-26 1998-07-07 Merck & Co., Inc. 4-oxa and 4-thia steriods
US5780437A (en) * 1995-12-14 1998-07-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US5756507A (en) * 1995-12-14 1998-05-26 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US5849764A (en) * 1995-12-14 1998-12-15 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200128919A (ko) 2019-05-07 2020-11-17 (주)케어젠 트롤록스-펩타이드 결합체 및 그의 용도

Also Published As

Publication number Publication date
MY123960A (en) 2006-06-30
CO4290359A1 (es) 1996-04-17
MY138240A (en) 2009-05-29
US6355649B1 (en) 2002-03-12
YU49026B (sh) 2003-07-07
YU58394A (en) 1999-11-22
EP0776664A3 (ko) 1997-06-11
EP0776664A2 (en) 1997-06-04
US5547957A (en) 1996-08-20
ZA948064B (en) 1995-06-06
HK1000933A1 (en) 1998-05-08
KR100375083B1 (ko) 2003-06-09
US6174892B1 (en) 2001-01-16
US20020042425A1 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
KR960704555A (ko) 5-알파 환원효소 억제제를 사용한 안드로겐성 탄모증의 치료 방법(Method of treating androgenic alopecia with 5-alpha reductase inhibitors)
KR910004651A (ko) 5α-환원효소 억제제로서의 17β-아실-4-아자-5α-안드로스트-1-엔-3-온
RU2397176C2 (ru) Стероидные фармацевтические продукты, направленные на спираль 12
ES2149208T3 (es) Inhibidores 4-azaesteroides de 5-alfa-reductasa.
US5760046A (en) Method of treating androgenic alopecia with 5-αreductase inhibitors
ATE198601T1 (de) Ester derivate von 4-aza-steroiden
RU94046057A (ru) Ингибиторы активности тестостерон 5 альфа -редуктазы, фармкомпозиция, способ подавления активности, тестостерон 5 альфа -редуктазы
DE69326008T2 (de) 17-amino-substituierte 4-azasteroide als 5-alpha-reductase inhibitoren
JP2004035566A (ja) インドールカルボキシル化合物とその製薬化合物としての用途
DE69519728D1 (de) 17 beta-aryl-4-aza-steroidderivate
KR970702273A (ko) 인돌 유도체 및 이를 함유하는 제제(indole derivative and medicine containing the same)
KR960700213A (ko) 항-안드로겐성 일고리-및 이고리-알켄(Anti-androgenic cyclo and bicyclo alkenes)
RU95110751A (ru) Новые 17бета -замещенные производные 4-азандростана, фармацевтические составы, содержащие их, и способ их получения
JP2000229857A (ja) テストステロン−５α−レダクターゼ阻害剤
KR930004269A (ko) 헥사하이드로벤조[에프] 퀴놀리논
DE69615046D1 (de) 17-alkyl-7-substituierte-4-aza-steroidderivate
JPH02193920A (ja) ５α―リダクターゼ阻害剤
ES2099007A1 (es) Derivados de indol.

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
AMND Amendment
B601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20010629

Effective date: 20021126

Free format text: TRIAL NUMBER: 2001101002031; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20010629

Effective date: 20021126

S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
GRNT Written decision to grant
O035 Opposition [patent]: request for opposition
O132 Decision on opposition [patent]
O074 Maintenance of registration after opposition [patent]: final registration of opposition
G171 Publication of modified document after post-grant opposition [patent]
J204 Request for invalidation trial [patent]
J204 Request for invalidation trial [patent]
J301 Trial decision

Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20041230

Effective date: 20070807

Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20050328

Effective date: 20070807

Free format text: TRIAL NUMBER: 2004100002894; TRIAL DECISION FOR INVALIDATION REQUESTED 20041230

Effective date: 20070807

Free format text: TRIAL NUMBER: 2005100000653; TRIAL DECISION FOR INVALIDATION REQUESTED 20050328

Effective date: 20070807

J2X1 Appeal (before the patent court)

Free format text: INVALIDATION

Free format text: TRIAL NUMBER: 2007200007426; INVALIDATION

Free format text: TRIAL NUMBER: 2007200007433; INVALIDATION

J2X2 Appeal (before the supreme court)

Free format text: APPEAL BEFORE THE SUPREME COURT FOR INVALIDATION

Free format text: TRIAL NUMBER: 2008300002039; APPEAL BEFORE THE SUPREME COURT FOR INVALIDATION

Free format text: TRIAL NUMBER: 2008300002015; APPEAL BEFORE THE SUPREME COURT FOR INVALIDATION

EXTG Ip right invalidated
J302 Written judgement (patent court)

Free format text: JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20070827

Effective date: 20080522

Free format text: TRIAL NUMBER: 2007200007433; JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20070827

Effective date: 20080522

J303 Written judgement (supreme court)

Free format text: JUDGMENT (SUPREME COURT) FOR INVALIDATION REQUESTED 20080617

Effective date: 20081009

Free format text: TRIAL NUMBER: 2008300002015; JUDGMENT (SUPREME COURT) FOR INVALIDATION REQUESTED 20080617

Effective date: 20081009

J302 Written judgement (patent court)

Free format text: JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20070827

Effective date: 20080522

Free format text: TRIAL NUMBER: 2007200007426; JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20070827

Effective date: 20080522